Key result
Serum chitotriosidase linked to ~18.8-fold higher 1-year mortality after coronary angiography.
Why the study?
Inflammation, macrophage activation, and angiogenic remodeling play central roles in CAD progression and plaque instability, and biomarkers reflecting these pathways may improve risk stratification beyond conventional clinical assessment. This study evaluated the combined diagnostic and prognostic significance of chitotriosidase, resistin, and VEGF-A in patients undergoing coronary angiography.
Does the combined assessment of serum chitotriosidase, resistin, and VEGF-A predict disease severity and one-year all-cause mortality in patients undergoing coronary angiography?
Cohort (n=275)
Does the combined assessment of serum chitotriosidase, resistin, and VEGF-A predict disease severity and one-year all-cause mortality in patients undergoing coronary angiography?
Measuring inflammatory and angiogenic biomarkers, particularly chitotriosidase, prior to coronary angiography provides incremental prognostic value beyond conventional markers for predicting one-year all-cause mortality across the CAD spectrum.
Answers are grounded in this paper and cite their sources.
May refine 1-year mortality stratification in angiography patients; hypothesis-generating and requires prospective validation before adoption.
Background Inflammation, macrophage activation, and angiogenic remodeling play central roles in coronary artery disease (CAD) progression and plaque instability. Biomarkers reflecting these complementary biological pathways may improve risk stratification beyond conventional clinical assessment. We evaluated the combined diagnostic and prognostic significance of chitotriosidase (CHIT), resistin (RTN), and vascular endothelial growth factor-A (VEGF-A) in patients undergoing coronary angiography. Methods In this prospective observational cohort, 275 consecutive patients undergoing coronary angiography were categorized as normal coronary arteries or CAD, including stable angina pectoris (SAP), unstable angina pectoris (UAP), non–ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). Serum CHIT, RTN, and VEGF-A levels were measured before angiography. Patients were followed for one-year all-cause mortality. Prognostic performance was evaluated using receiver operating characteristic analysis and Cox proportional hazards models. Results All biomarkers were significantly higher in CAD compared with controls and demonstrated a progressive increase from SAP to STEMI presentations (p<0.001). ROC analysis showed good discriminatory performance for mortality prediction (AUC: VEGF-A 0.773, CHIT 0.740, Troponin 0.742, RTN 0.703). In multivariable Cox regression analysis, CHIT remained the only independent predictor of adverse outcome (HR 18.8, 95% CI 2.48–142.34, p=0.005). Addition of CHIT significantly improved prognostic discrimination (C-index increase from 0.64 to 0.79; ΔC=0.15, p<0.001). Kaplan–Meier analysis confirmed significantly higher mortality among patients with elevated biomarker levels. Conclusion Combined assessment of inflammatory and angiogenic biomarkers reflects biological disease activity across the CAD spectrum and provides incremental prognostic value beyond conventional markers. Multimarker evaluation may enhance individualized risk stratification in patients undergoing coronary angiography.
No takes yet. Share an insight, caveat, or question.
Yildiz et al. (2026) conducted a cohort in Coronary artery disease (CAD) (n=275). Serum chitotriosidase (CHIT), resistin (RTN), and vascular endothelial growth factor-A (VEGF-A) levels vs. Normal coronary arteries / conventional markers was evaluated on One-year all-cause mortality (HR 18.8, 95% CI 2.48-142.34, p=0.005). Serum chitotriosidase independently predicted 1-year mortality in patients undergoing coronary angiography (HR 18.8; 95% CI 2.48-142.34; p=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: